Cellyan Biotechnology Co., Ltd (HKPD)

Every figure this model derived for HKPD, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 69,916 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2025-03-31
cash 190,912 CashAndCashEquivalents 2025-09-30
current assets 8,857,532 CurrentAssets 2025-09-30
current liabilities 3,026,121 CurrentLiabilities 2025-09-30
equity 5,143,431 EquityAttributableToOwnersOfParent 2025-09-30
interest expense 97,667 FinanceCosts 2025-03-31
ocf 569,214 CashFlowsFromUsedInOperatingActivities 2025-03-31
revenue 20,313,818 Revenue 2025-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up HKPD on one particular measure came for.

RatioValue
cash operating margin0.98
current ratio2.93
current ratio reported2.93
dilution pct38.59
ebit cagr-64.41
ebit yoy-91.79
fcf margin2.46
interest cover1.35
net debt ebitda12.3
operating margin0.65
owner earnings margin2.46
revenue growth21.72
revenue growth per share-12.17
roic1.38
rule of 4022.37
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about HKPD's figures. Written by the derivation as it ran, not added afterwards.